NTT: CEOs See Major Opportunities in Emerging Technologies to Tackle Social Challenges
WSJ Intelligence undertook a new international CEO survey for global technology and business solution provider NTT (TOKYO:9432). The survey focused on the dire necessity for complex digital technologies that have made it possible for businesses and societies to keep functioning amid the Covid-19 global pandemic.
WSJ Intelligence's global survey included 352 CEOs of large corporations representing ten major industries, across fifteen countries. The CEOs surveyed were asked about their corporation's role in society, their social-impact strategies, the stakeholders involved, and how those strategies were affected by the pandemic. This survey also examined the CEOs' confidence in a range of new and emerging technologies, and how those innovations might help the world to tackle enormous social challenges, such as the global supply chain, the future of work and health and well-being.
Key Findings:
- 56% of respondents believe corporations generate value by earning profits in a sustainable way that includes minimizing harm to society;
- 80% of stakeholder-centric executives say they pursue parallel financial and community outcomes, and see social-impact strategies as essential to financial returns;
- Technology powers the tools and opportunities to tackle social issues, but can also disrupt social stability through the rapid spread of false or misleading information;
- Cybersecurity is the only technology that a majority of executives consider fully adequate for their social-impact strategy; however adoption of cybersecurity technologies is not fast enough or sufficiently complete yet
- High-performance communications networks, followed by cloud computing and advanced analytics, are identified by CEOs as promising technologies with which to address social issues.
As the world continues to combat Covid-19 and plan for recovery, digital technology and social-impact programs will help to create the "new normal." The recovery from Covid-19 presents every organization with the opportunity to think in new ways and accelerate digital transformation.
About This Research
This research was conducted in July/August 2020 among CEOs across 15 countries, who participated in an online survey that aimed to understand how they viewed their company's responsibility to contribute, visibly and substantively, to achieving societal goals. Globally, 352 CEOs at companies with more than US$500M in revenue (with 75 of U.S. respondents at companies with more than $1BN) participated in quantitative research across 10 industries. "Investor-centric" respondents were defined as those whose view of the corporation is strictly to create value for shareholders by earning profit. "Stakeholder-centric" respondents answered either: "To create value for all stakeholders by earning profits in a sustainable way, which includes minimizing the harm that the business causes to society" or "Contribute to solutions for the challenges confronting people and society as a means of earning profits and generating long-term stakeholder value", when asked for their view of the role of the corporation in global society today.
[Reference]
READ THE WHITE PAPER (PDF: 2MB)
About WSJ Intelligence
WSJ Intelligence conducts bespoke and secondary research for brands and client brands of The Wall Street Journal | Barron's Group. Through rigorous analysis, WSJ Intelligence provides insights that are relevant, timely, and reliable.
About NTT
NTT believes in contributing to society through our business operations. We help people, clients and communities move confidently into the digital future and shape a better world. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data centers and networks. As a top-5 global technology and business solutions provider, our diverse team of over 300,000 people operates in 80+ countries and regions and delivers services to over 190 of them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217006234/en/
Contact information
Yuzo Aramaki
Associate Manager
Press Relations of NTT Corporation
Mail: ntt-cnr-ml@hco.ntt.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 02:00:00 EET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 23:30:00 EET | Press release
Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the cornerstone of Australia’s secure military communications since IS-22’s launch in 2012. SES will build a dedicated ground segmen
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 23:05:00 EET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 21:00:00 EET | Press release
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 20:32:00 EET | Press release
Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112241557/en/ Ricimed - Fabentech Ricimed®, an antidote against one of the most toxic natural substances in the world In addition to supportive care, and in severe situations requiring immediate administration, Ricimed® represents a new therapeutic option for the management of acute ricin intoxication. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Having demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs, Ricimed® is an antibody-based therapy relying on poly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
